[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
December 1988

Prophylaxis of Serious Cytomegalovirus Infection in Renal Transplant Candidates Using Live Human Cytomegalovirus VaccineInterim Results of a Randomized Controlled Trial

Author Affiliations

From the Departments of Surgery (Drs Brayman, Dafoe, Smythe, Barker, Perloff, Naji, and Fox) and Medicine (Drs Grossman and Jorkasky), Hospital of the University of Pennsylvania, and the Division of Infectious Diseases, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine (Drs Starr, Friedman, and Plotkin), Philadelphia.

Arch Surg. 1988;123(12):1502-1508. doi:10.1001/archsurg.1988.01400360072012
Abstract

• We report the interim results of a randomized, double-blind, placebo-controlled, clinical trial of prophylactic, live, attenuated cytomegalovirus (CMV) vaccination (Towne strain of CMV) of renal transplant candidates (RTCs). One hundred seventy-two RTCs were treated and subsequently underwent transplantation and followed up for at least one year and up to five years after transplantation. Eighty-eight RTCs received vaccine, and 84 received placebo. Results were analyzed according to the prevaccination serologic status (anti—CMV antibody titer) of the recipient (R − or R +) and the donor (D − or D+). The overall incidence of CMV disease was highest in the R−D+ group and almost absent in the R−D− group. There was no difference in the incidence of CMV infection or disease between vaccinated and respective placebo control recipients in either the R−D+, R+D+, R+D−, or R−D− groups. In contrast, the severity of CMV disease was significantly decreased in R−D+ vaccinees vs R−D+ placebotreated recipients. Moreover, in the R−D+ group, one- and five-year cadaver renal allograft actuarial survival rates were 73% and 62%, respectively, for CMV vaccinees vs 40% and 25%, respectively, for control placebo patients. We conclude that seronegative cadaver RTCs may benefit from vaccination with live, attenuated, Towne strain CMV vaccine before transplantation.

(Arch Surg 1988;123:1502-1508)

References
1.
Glenn J:  Cytomegalovirus infections following renal transplantation . Rev Infect Dis 1981;3:1151-1178.Article
2.
Betts RF, Freeman RB, Douglas RG, et al:  Clinical manifestations of renal allograft—derived primary cytomegalovirus infection . AJDC 1977;131: 759-763.
3.
Suwansirikul S, Rao N, Dowling JN, et al:  Primary and secondary cytomegalovirus infection: Clinical manifestations following renal transplantation . Arch Intern Med 1977;137:1026-1029.Article
4.
Chatterjee SN, Fiala M, Weiner J:  Primary cytomegalovirus and opportunistic infections: Incidence in renal transplant recipients . JAMA 1978;240:2446-2449.Article
5.
Fryd DS, Peterson PK, Ferguson RM, et al:  Cytomegalovirus as a risk factor in renal transplantation . Transplantation 1980;30:436-439.Article
6.
Peterson PK, Balfour HH Jr, Marker SC, et al:  Cytomegalovirus disease in renal allograft recipients: A prospective study of clinical features, risk factors, and impact on renal transplantation . Medicine 1980;59:283-300.Article
7.
Lopez C, Simmons RL, Mauer SM, et al:  Association of renal allograft rejection with virus infections . Am J Med 1974;56:280-289.Article
8.
Smiley ML, Wlodaver CG, Grossman RA, et al:  The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation . Transplantation 1985;40:157-161.Article
9.
 Collaborative DHPG Treatment Study Group treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies . N Engl J Med 1986;314:801-805.Article
10.
Erice A, Jordan C, Chace BA, et al:  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts . JAMA 1987;257:3082-3087.Article
11.
Cheeseman SH, Rubin RH, Stewart JA, et al:  Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation: Effects on cytomegalovirus and herpes simplex infections . N Engl J Med 1979;300:1345-1349.Article
12.
Hirsch MS, Schooley RT, Cosimi AB, et al:  Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients . N Engl J Med 1983;308:1489-1493.Article
13.
Snydman DR, Mclver J, Leszczynski J, et al:  A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients . Transplantation 1984;38:553-557.Article
14.
Snydman DR, Werner BG, Heinze-Lacey B, et al:  Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients . N Engl J Med 1988;317:1049-1054.Article
15.
Glazer JP, Friedman HM, Grossman RA, et al:  Live cytomegalovirus vaccination of renal transplant candidates: A preliminary trial . Ann Intern Med 1979;91:676-683.Article
16.
Plotkin SA, Smiley ML, Friedman HM, et al:  Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants . Lancet 1984;1:528-530.Article
17.
Plotkin SA, Farquar J, Hornberger E:  Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus . J Infect Dis 1976;134:470-475.Article
18.
Starr SE, Glazer JP, Friedman HM, et al:  Specific cellular and humoral immunity following immunization with live Towne strain cytomegalovirus vaccine . J Infect Dis 1981;143:585-589.Article
19.
Plotkin SA, Smiley ML, Friedman HM, et al:  Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine . Birth Defects 1984;20:271-287.
20.
Keltering JD, Schmidt NJ, Galls D, et al:  Anti-complement immunofluorescence test for antibodies to human cytomegalovirus . J Clin Microbiol 1977;6:627-632.
21.
Starr SE, Friedman HM:  Human cytomegalovirus , in Lennette EH, Balows A, Hausler W, et al: Journal of Pediatrics Manual of Clinical Microbiology , ed 3. Washington, DC, American Society of Microbiology, 1980,p 790.
22.
Balfour HH Jr, Sachs GW, Welo P, et al:  Cytomegalovirus vaccine in renal transplant candidates: Progress report of a randomized, placebocontrolled, double-blind trial . Birth Defects 1984;20:289-304.
23.
Rubin RH, Tolkoff-Rubin NE, Oliver D, et al:  Multi-center seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation . Transplantation 1985;40:243-249.Article
24.
Stratta RJ, Oh C, Sollinger HW, et al:  Kidney transplantation in the cyclosporine era . Transplantation 1988;45:40-45.Article
25.
Canadian Multi-Center Transplant Study Group:  A randomized clinical trial of cyclosporine in cadaveric renal transplantation . N Engl J Med 1983;309:809-815.Article
26.
Bia MJ, Andiman W, Gandio K, et al:  Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection post transplantation . Transplantation 1985;40:610-614.Article
×